Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes
Primary resultResult — go to the resultReduction in EAT glucose uptake 21.6%Authors' conclusion
SGLT-2 inhibition selectively reduces EAT thickness and EAT glucose uptake in T2D patients, suggesting a reduction of EAT inflammation. This could explain the observed increase in myocardial flow reserve, providing new insights into SGLT-2i cardiovascular benefits.
Study context
- Population
- T2D patients with stable coronary artery diseaserandomized 1:1
- Participants
- 14 patients
- Comparison
- Dapagliflozin 10 mg daily vs placebo
Methodological detailssingle-center, prospective, double-blind
- Single-center
- Prospective
- Double-blind
Primary result
As reported in the abstract
4 weeks
Reduction in epicardial adipose tissue (EAT) glucose uptake
21.6%
P = 0.014
- Dapagliflozin significantly reduced EAT thickness
- 19% (p = 0.03)
Further findings
Adipose tissue thickness/metabolism in other depots (mediastinal, perirenal, subcutaneous) · 4 weeks
- No significant effects on adipose tissue thickness/metabolism in the other depots explored
Original publication
Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes. Cardiovasc Diabetol. Published 19 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →